GlassScriptPhysician profile
Farley W Brown
NPI 1265467385
$4,826.86
in general payments reported to CMS, 2019-2025
30 companies · $862 in 2025
The $862 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.27 · 2020: $40.85 · 2021: $1,177 · 2022: $874 · 2023: $1,231 · 2024: $630 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,682 · Education: $40.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,682.47 |
| Education | $40.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,212.32 | 2021-2025 | |
| Novo Nordisk INC | $1,174.74 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $559.06 | 2021-2025 | Farxiga, Airsupra, Lokelma |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $291.90 | 2023-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $280.89 | 2024-2025 | |
| Astellas Pharma US INC | $184.86 | 2023-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $179.29 | 2021-2025 | Xifaxan |
| Eisai INC. | $124.76 | 2021-2022 | |
| Lilly USA, LLC | $115.08 | 2023 | Mounjaro |
| Biohaven Pharmaceutical Holding Company LTD. | $94.04 | 2022 | |
| Genentech USA, INC. | $89.03 | 2020-2021 | |
| Pfizer INC. | $61.18 | 2023-2024 | |
| Shield Therapeutics INC | $56.83 | 2022-2023 | Accrufer |
| Tolmar, INC. | $48.93 | 2025 | Jatenzo |
| Antares Pharma, INC. | $37.31 | 2023-2025 | Xyosted, Tlando, Nocdurna |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $37.24 | 2021 | |
| Ibsa Pharma INC. | $31.43 | 2022-2024 | Tirosint, Licart |
| Merck Sharp & Dohme LLC | $30.48 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $29.89 | 2021 | |
| Exact Sciences Corporation | $19.87 | 2025 | The Cologuard Plus Collection Kit |
| Upsher-Smith Laboratories LLC | $19.84 | 2022 | |
| Abbott Laboratories | $19.77 | 2024 | Id Now Instrument |
| Inogen, INC. | $19.72 | 2022 | |
| Gilead Sciences, INC. | $19.26 | 2025 | |
| Glaxosmithkline, LLC. | $19.20 | 2024 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $18.13 | 2025 | Rexulti |
| Aytu Biopharma, INC. | $15.63 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.27 | 2021 | |
| Currax Pharmaceuticals LLC | $11.64 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farley Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.